Melanoma Reagents | abinScience

Главная > Рекомендуемая продукция > Oncology Research > Меланома

960 результатов продукта для "Меланома"

Опции+

Опции

Подтвердить

Типы продуктов

0 выбран

Antibodies (298)

Stable Cell Lines (1)

Assay Kit (419)

Proteins (75)

Biosimilars (1)

Research Biosimilar (157)
Система экспрессии

0 выбран

Mammalian Cells (186)

HEK293T (1)

E. coli (35)
Цель

0 выбран

TRP-1 & CD3e (1)

S100P (1)

CD223/LAG3 & CD152/CTLA4 (1)

S100A10 (4)

Lintuzumab (1)

CD274/PD-L1 & CD47/MER6 (1)

CD274/PD-L1 & SLT-Ia (1)

CD80/B7-1 (20)

Oxelumab (1)

Panitumumab (3)

Ixekizumab (1)

Siltuximab (3)

Suvizumab (1)

CD47/MER6 & PDCD1 / PD-1 & CD137/4-1BB/TNFRSF9 (1)

Ibritumomab (1)

RBD (Omicron/BA.4/BA.5) (1)

CD278/ICOS (1)

Itolizumab (1)

TPP15 (1)

Anetumab (1)

Zanolimumab (1)

Blosozumab (1)

Lacnotuzumab (1)

Iscalimab (1)

Olaratumab (1)

Glycoprotein (5)

PMEL17/ME20M (9)

Protein A (1)

Tisotumab (1)

RBD (Kappa) (1)

Ramucirumab (1)

Nesvacumab (1)

Pembrolizumab (3)

mitF/aspF1 (1)

Milatuzumab (1)

Avelumab (3)

Befovacimab (1)

Casirivimab (1)

Bimagrumab (1)

gC/Envelope glycoprotein C (1)

Utomilumab (1)

Gevokizumab (1)

Tezepelumab (1)

Teprotumumab (1)

IL6 (1)

Bevacizumab (3)

SARS-CoV-2 Neutralization Antibody (3)

Ivuxolimab (1)

PDL1 & VEGF (1)

Ieramilimab (1)

CD274/PD-L1 & VEGFA (1)

TYRP1 (3)

CD19 & PD-L1 & CD3E & CD137 (1)

S100A9 (4)

Asp f 1/mitF (1)

CD274/PD-L1 & CD134/OX40 (1)

CD274/PD-L1 & CD28 & CD152/CTLA4 (1)

CD47/MER6 & CD274/PD-L1 (2)

S100A16 (1)

HLA-A2-peptide (TDQVPFSV) Complex (1)

Pogalizumab (1)

Serclutamab (1)

Remtolumab (1)

Clazakizumab (1)

Mosunetuzumab (1)

TPP17 (1)

Conatumumab (1)

Romosozumab (1)

TYR (1)

Romiplostim (2)

Tovetumab (1)

M/Matrix protein (2)

CD3E (1)

Belantamab (1)

PD-L1 / VEGF-A (1)

Certolizumab (2)

Enoblituzumab (1)

Cabiralizumab (1)

Gremubamab (1)

Human β Amyloid (1-42) (1)

RBD (Delta Plus) (1)

Spike glycoprotein (RBD) (1)

Vanucizumab (1)

Sintilimab (1)

Glycoprotein G (2)

Durvalumab (3)

CD80&IL2 (1)

Concizumab (1)

Imdevimab (1)

CD117/KIT (24)

Rolinsatamab (1)

gC/UL44 (1)

Magrolimab (1)

CD20/MS4A1 (3)

Etanercept (3)

Brolucizumab (1)

RBD (Omicron/BA.5) (3)

HLA-A2-peptide (ITDQVPFSV) Complex (4)

EGFR & CD3E & PD-L1 & 4-1BB (1)

CD366/TIM-3 & CD274/PD-L1 (1)

TRP-1 & CD47/MER6 (1)

CD274/PD-L1 & CD279/PD-1 (1)

Oleclumab (1)

IDO1 (2)

CD366/TIM-3 & CD279/PD-1 (2)

Sarilumab (2)

CD152/CTLA4 & CD279/PD-1 (1)

Ranibizumab (3)

NP/Nucleoprotein (3)

Tavolimab (1)

Secukinumab (2)

Imlifidase (5)

Olokizumab (1)

Foravirumab (1)

CD47/MER6 & CD274/PD-L1/B7-H1 (2)

Ocaratuzumab (1)

Elotuzumab (1)

Cusatuzumab (1)

TPP47 (1)

Drozitumab (1)

Ontamalimab (1)

Eldelumab (1)

Sacituzumab (1)

Eculizumab (3)

Varlilumab (1)

Tirzepatide (2)

gp100 peptide-HLA Complex (1)

Teclistamab (1)

Mirzotamab (1)

CD223 (1)

Emactuzumab (1)

M1R (5)

Human β Amyloid (1-40) (1)

Imalumab (1)

Semaglutide (2)

Ascrinvacumab (1)

TFF3 (1)

Tislelizumab (1)

Disitamab (1)

Pacmilimab (1)

TDP2 (1)

Marstacimab (1)

Daratumumab (3)

gD/US6 (1)

Basiliximab (1)

Elezanumab (1)

Apamistamab (1)

HLA-A2-peptide (YLEPGPVT) Complex (4)

Calprotectin (S100A8/9) (3)

BRAF/B-Raf (5)

Mavezelimab (1)

CD137/4-1BB & CD274/PD-L1 (3)

TRP-1 & CD134/OX40 (1)

CD274/PD-L1 & TGFBR2/TGFR-2 (1)

CD80/B7-1 & CD86/B7-2 (2)

S100A11 (2)

RBD (6)

Varisacumab (1)

RBD (Omicron/JN.1) (1)

Lirilumab (1)

CTLA4 & PD1 (2)

Tesidolumab (1)

Sirukumab (1)

Rafivirumab (1)

cAMP (1)

RBD (WT) (1)

Vorsetuzumab (1)

G/Major surface glycoprotein G (1)

Lexatumumab (1)

Mirikizumab (2)

PDL1 (6)

Aflibercept (1)

Ipilimumab (2)

GP/Envelope glycoprotein (4)

T3E (1)

Golimumab (3)

Omburtamab (1)

TAU pT181 (1)

Evolocumab (1)

EPO/Erythropoietin (1)

Lupartumab (1)

Toripalimab (1)

Exenatide acetate (2)

Pertuzumab (3)

CD137/4-1BB/TNFRSF9& CD274/PD-L1/B7-H1 (1)

Denosumab (3)

US8/gE (1)

Sibrotuzumab (1)

Fluorescein & CD274/PD-L1 (1)

Camidanlumab (1)

Mazdutide (2)

Omalizumab (2)

HLA-A2-peptide (KTWGQYWQV) Complex (2)

Favezelimab (1)

CD86/B7-2 (26)

CD152/CTLA4 & CD274/PD-L1 (1)

Zampilimab (1)

NRAS (2)

CD175/Tn (10)

S100A6 (1)

LAG3 & PD-1 (1)

Daclizumab (1)

Enfortumab (1)

Emibetuzumab (1)

RBD (Delta) (3)

FLT1/VEGFR1 & CD274/PD-L1 (1)

RBD (Omicron/KP.2) (1)

Tibulizumab (1)

Ziltivekimab (1)

VASH2/Vasohibin-2 (1)

Carlumab (1)

RBD (Alpha) (1)

N/Nucleoprotein (1)

Tigatuzumab (1)

Glembatumumab (1)

Lenzilumab (1)

Semorinemab (1)

Talacotuzumab (1)

S100A5 (4)

Tremelimumab (1)

gG/US4 (2)

T-cell surface antigen T3/Leu-4 epsilon chain (1)

Pasotuxizumab (1)

TIGIT & CD274/PD-L1 (1)

Cixutumumab (1)

H3L (3)

TAU pT217 (1)

Andecaliximab (1)

Alirocumab (1)

Cinpanemab (1)

CD274/PD-L1 & CD28 (1)

TYR/Tyrosinase (2)

Trastuzumab (2)

Nirsevimab (1)

CD47/MER6 & PDCD1 / PD-1 / CD279 (1)

Obinutuzumab (2)

Cetuximab (3)

Ifabotuzumab (1)

CD366/HAVCR2/TIM-3 (4)

Spike glycoprotein E2 (2)

Simlukafusp Alfa (1)

CD152/CTLA4 & CD134/OX40 (1)

Rituximab (1)

CD274/PD-L1 & CD137/TNFRSF9 (1)

S100A12 (1)

S100A14 (1)

CD274/PD-L1 (81)

Anifrolumab (1)

S100a15a (1)

Spike glycoprotein E1 (2)

Spike glycoprotein (10)

Crizanlizumab (1)

CD340/ERBB2 (1)

Codrituzumab (1)

Tanezumab (1)

Vunakizumab (1)

Tosatoxumab (1)

SOX10 (3)

RBD (Beta) (1)

Meplazumab (1)

Balstilimab (1)

Namilumab (1)

Dilpacimab (1)

Tilavonemab (1)

Natalizumab (2)

S100A8 (3)

Vibecotamab (1)

Zalifrelimab (1)

gB/Envelope glycoprotein B (1)

T-cell surface glycoprotein CD3 epsilon chain (1)

Rosopatamab (2)

Infliximab (2)

Frovocimab (1)

Dalotuzumab (1)

E8L (5)

S100A2 (1)

Depatuxizumab (1)

Retatrutide (1)

Zanidatamab (1)

Palivizumab (3)

KITLG/SCF (1)

Afutuzumab (1)

sCD14 (1)

CD366/TIM-3 (34)

Abatacept (1)

S100A13 (1)

S100A4 (3)

CD274/PD-L1 & CD152/CTLA4 (1)

Indatuximab (1)

S100B (9)

CD223/LAG3 (41)

CD279/PD-1 & CD274/PD-L1 (1)

CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)

S100A1 (2)

Vofatamab (1)

CD223/LAG3 & CD279/PD-1 (4)

F/Fusion glycoprotein F0 (5)

Letolizumab (1)

dsRNA (1)

Ibalizumab (1)

Ianalumab (1)

Tocilizumab (3)

Spike Protein (Trimer) (2)

Dupilumab (3)

Inclacumab (1)

IL1RL1/ST2 (1)

VSIR/VISTA & CD274/PD-L1 (1)

Cergutuzumab (1)

cGMP (1)

Lorvotuzumab (1)

RBD (Gamma) (1)

MITF (1)

Cetrelimab (1)

DCT (2)

Otilimab (1)

Navicixizumab (1)

VEGFA & B7-H1 / PD-L1 / CD274 (1)

Zagotenemab (1)

gE/Envelope glycoprotein E (1)

Tarextumab (1)

Lodelcizumab (1)

PD-L1 & VEGF (1)

Figitumumab (1)

A35R (5)

Farletuzumab (1)

Ustekinumab (3)

CD79B (2)

Losatuxizumab (1)

Afasevikumab (1)

β-D-Glucan (1)

Suptavumab (1)

B7-H1 / PD-L1 / CD274 & CD3E (1)

Epcoritamab (1)

Icrucumab (1)

CD152/CTLA4 (86)

CD274/PD-L1 & TGFBR2 (1)

CD279/PD-1 & CD152/CTLA4 (4)

CD274/PD-L1 & CD3E (1)

p-Tyr (1)

Glofitamab (1)

Guselkumab (3)

ATP7B (1)

Benufutamab (1)

Amatuximab (1)

Tregalizumab (1)

PD-L1 & TGF-Beta (1)

NP/Nucleocapsid (5)

dsDNA (1)

Astegolimab (1)

Adalimumab (3)

Tiragolumab (2)

Labetuzumab (1)

Obiltoxaximab (1)

BSA (1)

RBD (E484K) (1)

Alacizumab (1)

Faricimab (1)

Nivolumab (3)

Atezolizumab (3)

Sotrovimab (1)

MLANA (4)

Edrecolomab (1)

gD/Envelope glycoprotein D (1)

Urelumab (1)

Canakinumab (1)

LAG-3 & PD-1 (1)

Ganitumab (1)

A29L (6)

Mirvetuximab (1)

B6R/SL-159 (1)

CD274/PD-L1/B7-H1 (5)

Necitumumab (1)

Bimekizumab (1)

Zenocutuzumab (1)
Виды

0 выбран

Cat (1)

Mouse (27)

Canis lupus familiaris (1)

Rat (1)

Neosartorya fumigata (1)

Tupaia chinensis (12)

Mus musculus (Mouse) (7)

Canis lupus familiaris (Dog) (8)

Homo sapiens (Human) (7)

Dog (3)

Human (178)

Felis catus (Cat) (9)
Применения

0 выбран

IP (2)

SDS-PAGE (75)

Bioactivity: FACS (1)

Functional assay (158)

in vitro PD-L1 blockade (3)

FACS (5)

Иммуноген (75)

Research in vivo (158)

IHC-F (3)

IF (8)

Functional assay (6)

Bioactivity testing in progress (31)

Research in vivo (4)

Neutralization (2)

Blocking (2)

in vivo CTLA-4 neutralization (2)

ELISA (844)

GICA (2)

in vivo (2)

in vivo intra-tumoral regulatory T cell depletion (2)

in vivo blockade (2)

Neut (1)

FCM (152)

IHC (84)

FuncS (18)

Inhib (1)

WB (165)

IFA (4)

SPR (4)

Bioactivity: FACS (153)

in vivo PD-L1 blockade (3)
Реактивность

0 выбран

Capra hircus (1)

Oryzias latipes (1)

Danio rerio (1)

Broad-Spectrum (1)

Xenopus laevis (1)

Macaca mulatta (1)

Drosophila grimshawi (1)

Bovine (1)

Rat (16)

Drosophila willistoni (1)

Neosartorya fumigata (1)

Homo sapiens (Human) (4)

Monkey (5)

Kirsten murine sarcoma virus (1)

Cat (1)

Kryptolebias marmoratus (1)

Avian retrovirus IC10 (1)

Chicken (4)

Limanda limanda (1)

Avian rous-associated virus type 1 (1)

Carassius auratus (1)

Tupaia chinensis (4)

Pig (6)

Mesocricetus auratus (1)

Bos taurus (8)

Coturnix japonica (1)

Cavia porcellus (1)

Mouse (77)

Cynomolgus monkey (1)

Dog (13)

Human (198)

Callithrix jacchus (1)

Monodelphis domestica (1)

Oryctolagus cuniculus (4)

Pongo abelii (2)

Cyprinus carpio (1)

B7-H1 / PD-L1 / CD274 (1)

Rhesus macaque (1)

Mus musculus (Mouse) (1)
Хозяинский вид

0 выбран

Chimeric (5)

Rat (14)

Humanized (34)

Alpaca (6)

HEK293T (1)

Human (157)

Dog (2)

Mouse (164)

Rabbit (61)

Armenian Hamster (5)
Клоональность

0 выбран

Polyclonal (53)

Monoclonal (398)
Конъюгат

0 выбран

PE (28)

FITC (28)

APC (28)

PerCP (28)

Unconjugated (301)